Flutiform - Results of Safety Study
Frank Condella, CEO of SkyePharma said, 'The results of this study are as we expected and represent a significant milestone achieved in the FlutiformTM development programme. We continue to make good progress towards the approval of this exciting product.'
For further information please contact:
SkyePharma PLC
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer +44 207 491 1777
Peter Grant, Finance Director
Financial Dynamics (London enquiries) David Yates / Deborah Scott
+44 207 831 3113
Trout Group (US enquiries) Christine Labaree / Seth Lewis +1 617
583 1308
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma
develops new formulations of known molecules to provide a clinical
advantage and life-cycle extension. The Company has eleven approved
products in the areas of oral, inhalation and topical delivery. The
Group's products are marketed throughout the world by leading
pharmaceutical companies. For more information, visit
www.skyepharma.com.
